Sun Pharma Launches Ezallor Sprinkle Capsules In U.S. For Difficulty Swallowing

(RTTNews) - Sun Pharmaceutical Industries Ltd. (SUNPHARMA, 524715) announced Monday the U.S. launch of Ezallor Sprinkle (rosuvastatin) capsules for people who have difficulty swallowing.

Ezallor Sprinkle is formulated as extended-release-coated pellets that may be sprinkled over soft food such as applesauce, can be swallowed whole, or administered via a nasogastric tube to facilitate long-term, once-daily administration.

Sun Pharma said it is the first and only FDA-approved sprinkle formulation of rosuvastatin.

It is the second product in the Sun Pharma portfolio designed for individuals in long-term care.

The capsules are indicated for the treatment of three types of elevated lipid disorders in conjunction with diet in adults. These include to treat hypertriglyceridemia, primary dysbetalipoproteinemia, and as an adjunct to other lipid-lowering treatments or as monotherapy if such treatments are unavailable to reduce LDL-C, total cholesterol, and ApoB in adult patients with homozygous familial hypercholesterolemia.

The company noted that Ezallor Sprinkle has not been studied in Fredrickson type I and V dyslipidemias.

Chris Chappel, certified Medical Director, Chappel Senior Care and Chappel Group Research, said, "The risk of medication errors increases when people have difficulty swallowing, due to crushing of medicines that shouldn't be crushed, or from residual medication left over in crushing devices. This formulation will help in administering medication for patients with common types of elevated lipid disorders, especially in the geriatric population."